BR112021026682A2 - Compostos e métodos para inibir eif4e - Google Patents

Compostos e métodos para inibir eif4e

Info

Publication number
BR112021026682A2
BR112021026682A2 BR112021026682A BR112021026682A BR112021026682A2 BR 112021026682 A2 BR112021026682 A2 BR 112021026682A2 BR 112021026682 A BR112021026682 A BR 112021026682A BR 112021026682 A BR112021026682 A BR 112021026682A BR 112021026682 A2 BR112021026682 A2 BR 112021026682A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
formula
eif4e
pharmaceutically acceptable
Prior art date
Application number
BR112021026682A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Grubbs
X Xiang Alan
Viet Tran Chinh
Christian Nilewski
Kenneth Packard Garrick
T Ernst Justin
Kaveri Urkalan
Mike Shaghafi
A Sprengeler Paul
Samuel Sperry
H Reich Siegfried
Takasuke Mukaiyama
Theo Michels
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of BR112021026682A2 publication Critical patent/BR112021026682A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021026682A 2019-07-02 2020-06-30 Compostos e métodos para inibir eif4e BR112021026682A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
PCT/US2020/040299 WO2021003157A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
BR112021026682A2 true BR112021026682A2 (pt) 2022-03-15

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026682A BR112021026682A2 (pt) 2019-07-02 2020-06-30 Compostos e métodos para inibir eif4e

Country Status (15)

Country Link
US (2) US11286268B1 (cg-RX-API-DMAC10.html)
EP (1) EP3994139A1 (cg-RX-API-DMAC10.html)
JP (1) JP7595055B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220061945A (cg-RX-API-DMAC10.html)
CN (1) CN114269756B (cg-RX-API-DMAC10.html)
AR (1) AR119339A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020299362B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021026682A2 (cg-RX-API-DMAC10.html)
CA (2) CA3188446A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003573A1 (cg-RX-API-DMAC10.html)
IL (1) IL289456A (cg-RX-API-DMAC10.html)
PY (1) PY2031844A (cg-RX-API-DMAC10.html)
TW (1) TWI748541B (cg-RX-API-DMAC10.html)
UY (1) UY38773A (cg-RX-API-DMAC10.html)
WO (1) WO2021003157A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
KR20230124648A (ko) * 2020-12-22 2023-08-25 화이자 인코포레이티드 Eif4e 억제제의 고체 형태
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
AU2023375677A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9540371B2 (en) 2013-04-29 2017-01-10 Vanderbilt University Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス, インコーポレイテッド 線維性疾患を治療するための方法
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Also Published As

Publication number Publication date
CA3188446A1 (en) 2021-01-07
JP7595055B2 (ja) 2024-12-05
US20230108594A1 (en) 2023-04-06
PY2031844A (es) 2021-04-19
CN114269756A (zh) 2022-04-01
CA3085255A1 (en) 2021-01-02
TW202115058A (zh) 2021-04-16
AR119339A1 (es) 2021-12-09
KR20220061945A (ko) 2022-05-13
TWI748541B (zh) 2021-12-01
WO2021003157A1 (en) 2021-01-07
UY38773A (es) 2021-01-29
AU2020299362A1 (en) 2022-02-24
IL289456A (en) 2022-02-01
US11286268B1 (en) 2022-03-29
AU2020299362B2 (en) 2026-02-26
CL2021003573A1 (es) 2022-08-12
EP3994139A1 (en) 2022-05-11
JP2022539256A (ja) 2022-09-07
CN114269756B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
CL2021003573A1 (es) Compuestos y métodos que inhiben eif4e
MX2020010805A (es) Inhibidores de bcl6.
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX376584B (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
EA201700077A1 (ru) Соединения аминопиримидинила в качестве ингибиторов jak
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
MX2019012827A (es) Derivados de tetrahidronaftilo urea novedosos.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]